NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AGIO

Agios Pharmaceuticals Inc

Jul 03 • 04:00PM ET

36.07

Dollar change +0.72
Percentage change 2.04	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN VRTX GILD ALNY SRPT NBIX BLUE FOLD NVAX

| Held by: VTI IWM VB VXF VBK XBI IWN IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	3.20	EPS (ttm)	11.29	Insider Own	4.37%	Shs Outstand	57.89M	Perf Week	7.19%
Market Cap	2.09B	Forward P/E	-	EPS next Y	-6.64	Insider Trans	-2.77%	Shs Float	55.39M	Perf Month	8.09%
Enterprise Value	1.25B	PEG	-	EPS next Q	-1.81	Inst Own	105.23%	Short Float	7.81%	Perf Quarter	26.83%
Income	665.99M	P/S	56.41	EPS this Y	-162.17%	Inst Trans	-5.78%	Short Ratio	7.24	Perf Half Y	9.20%
Sales	37.03M	P/B	1.42	EPS next Y	8.20%	ROA	55.38%	Short Interest	4.32M	Perf YTD	9.77%
Book/sh	25.33	P/C	2.34	EPS next 5Y	-	ROE	60.26%	52W High	62.58 -42.36%	Perf Year	-16.85%
Cash/sh	15.43	P/FCF	-	EPS past 3/5Y	- -	ROIC	44.33%	52W Low	23.42 54.05%	Perf 3Y	59.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -20.91%	Gross Margin	72.44%	Volatility	4.06% 3.97%	Perf 5Y	-30.25%
Dividend TTM	-	EV/Sales	33.72	EPS Y/Y TTM	285.73%	Oper. Margin	-1188.86%	ATR (14)	1.36	Perf 10Y	-65.84%
Dividend Ex-Date	-	Quick Ratio	17.93	Sales Y/Y TTM	25.96%	Profit Margin	1798.26%	RSI (14)	65.05	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	18.50	EPS Q/Q	-7.45%	SMA20	5.27%	Beta	0.79	Target Price	51.71
Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	6.56%	SMA50	14.04%	Rel Volume	0.43	Prev Close	35.35
Employees	488	LT Debt/Eq	0.02	Earnings	May 01 BMO	SMA200	-3.71%	Avg Volume	596.80K	Price	36.07
IPO	Jul 24, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.46% -10.12%	Trades		Volume	258,713	Change	2.04%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-25	Initiated	H.C. Wainwright	Buy	$58
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform	$51
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform	$60 → $56
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight	$41
Nov-17-22	Upgrade	Goldman	Sell → Neutral	$17 → $32
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$33
Dec-03-21	Initiated	BofA Securities	Buy	$54
Jul-30-21	Downgrade	Goldman	Neutral → Sell	$58 → $39
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy	$88
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$50
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral	$64 → $54
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight	$46
Mar-04-20	Initiated	Barclays	Equal Weight	$50
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight	$64
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy	$55
May-23-19	Resumed	Goldman	Neutral	$55

Show Previous Ratings

Jun-17-25 01:37PM	Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat's Market Potential (Insider Monkey)
Jun-15-25 05:43AM	H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT (Insider Monkey)
Jun-09-25 08:40AM	Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders (Business Wire)
Jun-05-25 11:31AM	Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 11:30AM	Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
07:00AM	Loading…
May-28-25 07:00AM	Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 (GlobeNewswire)
May-14-25 10:00AM	Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress (GlobeNewswire)
May-09-25 07:00AM	Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 (GlobeNewswire)
May-02-25 07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
07:00AM	Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 (GlobeNewswire)
03:02AM	Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
May-01-25 12:06PM	Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:50AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:47AM	Agios Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
10:02AM	Loading…
Apr-24-25 10:02AM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-17-25 07:00AM	Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 (GlobeNewswire)
Apr-08-25 06:24AM	New Strong Sell Stocks for April 8th (Zacks) -5.29%
Apr-03-25 03:54AM	New Strong Sell Stocks for April 3rd (Zacks)
Mar-27-25 05:35AM	Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? (Zacks)
Mar-26-25 09:39PM	Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-05-25 05:52PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer (GlobeNewswire)
Mar-04-25 07:00AM	Agios to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-01-25 09:20AM	Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-20-25 07:00AM	Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 (GlobeNewswire)
Feb-15-25 10:05AM	Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank (TipRanks)
Feb-14-25 02:09AM	Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Feb-13-25 12:45PM	Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years (Benzinga)
07:45AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:31AM	Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Loading…
06:30AM	Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint (GlobeNewswire)
Feb-12-25 10:25AM	Agios Pharmaceuticals price target lowered to $54 from $55 at BofA (TipRanks)
08:05AM	Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-06-25 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 (GlobeNewswire)
Jan-13-25 04:29PM	Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential (Insider Monkey)
07:00AM	Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio (GlobeNewswire)
Jan-08-25 07:00AM	FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia (GlobeNewswire)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal)
07:00AM	Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 (GlobeNewswire)
Dec-18-24 07:00AM	European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease (GlobeNewswire) -7.01%
Dec-10-24 09:39AM	Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank (TipRanks) -5.39%
Dec-09-24 04:21PM	Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug (Investor's Business Daily) -21.09%
Dec-08-24 12:40PM	Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat (GlobeNewswire)
Dec-05-24 08:42AM	Are Options Traders Betting on a Big Move in Agios (AGIO) Stock? (Zacks)
Nov-26-24 09:40AM	Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-05-24 09:05AM	Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-01-24 03:03AM	Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Oct-31-24 07:45AM	Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates (Zacks)
06:42AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-23-24 07:00AM	Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease (GlobeNewswire)
Oct-17-24 07:00AM	Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 (GlobeNewswire)
Sep-27-24 10:34AM	Do Options Traders Know Something About Agios (AGIO) Stock We Don't? (Zacks) -5.08%
Sep-26-24 04:05PM	Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. (Investor's Business Daily)
Sep-17-24 07:56AM	Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results (Insider Monkey)
Sep-12-24 06:33AM	Agios Pharmaceuticals tebapivat gains FDA orphan drug designation (Pharmaceutical Technology)
Sep-11-24 07:00AM	Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS) (GlobeNewswire)
Sep-05-24 07:00AM	Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024 (GlobeNewswire)
Aug-09-24 07:50AM	Agios Pharmaceuticals, Inc. (AGIO): Are Street Analysts Bullish on This Top Caligan Partner Holding Right Now? (Insider Monkey)
07:23AM	Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now? (Insider Monkey)
Aug-06-24 05:50PM	Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib (GlobeNewswire)
Aug-01-24 01:42PM	Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides (Benzinga)
07:45AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:43AM	Agios Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
06:31AM	Agios Reports Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire)
06:30AM	Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused (GlobeNewswire)
Jul-25-24 10:01AM	Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-24 07:00AM	Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jun-24-24 04:25AM	Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains? (Zacks)
Jun-15-24 08:45AM	Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress (GlobeNewswire)
Jun-07-24 07:00PM	Insider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc (AGIO) (GuruFocus.com)
Jun-06-24 09:00AM	Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET (GlobeNewswire)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
Jun-04-24 12:44PM	Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study (Zacks) +8.03%
Jun-03-24 06:30AM	Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia (GlobeNewswire) +20.61%
May-30-24 04:05PM	Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 (GlobeNewswire)
May-29-24 12:35PM	Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty (Zacks)
May-28-24 04:03PM	Agios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer Deal (Investor's Business Daily) +23.21%
12:20PM	Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 (Associated Press Finance)
09:46AM	Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out (Investor's Business Daily)
08:12AM	Agios cashes in on cancer drug again with $905M Royalty Pharma deal (BioPharma Dive)
07:00AM	Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty (GlobeNewswire)
May-24-24 09:55AM	How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43% (Zacks)
May-14-24 10:00AM	Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress (GlobeNewswire)
May-08-24 09:55AM	Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High? (Zacks)
May-06-24 07:00AM	Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024 (GlobeNewswire)
May-03-24 12:21PM	Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates (Zacks)
11:10AM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:00AM	Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 (GlobeNewswire)
03:03AM	Agios Pharmaceuticals Inc (AGIO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 10:45PM	Q1 2024 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
12:57PM	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss (MT Newswires)
11:56AM	AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:44AM	Agios Pharmaceuticals Reports Q1 2024 Earnings: Narrower Loss than Expected with Strong Revenue ... (GuruFocus.com)
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:29AM	Agios Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Agios Reports Business Highlights and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 10:02AM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-18-24 07:00AM	Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 (GlobeNewswire)
Apr-16-24 04:30PM	The 3 Best Biotech Stocks to Buy Now: Q2 Edition (InvestorPlace)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gheuens Sarah	Chief Medical Officer	Jul 01 '25	Option Exercise	0.00	8,374	0	65,362	Jul 03 04:01 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '25	Sale	34.17	4,091	139,789	61,271	Jul 03 04:01 PM
Gheuens Sarah	Officer	Jul 01 '25	Proposed Sale	34.37	4,091	140,608		Jul 01 04:03 PM
Burns James William	Chief Legal Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	31,449	Jun 26 05:26 PM
Burns James William	Chief Legal Officer	Jun 24 '25	Sale	33.54	2,799	93,878	28,650	Jun 26 05:26 PM
Gheuens Sarah	Chief Medical Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	59,897	Jun 26 05:25 PM
Gheuens Sarah	Chief Medical Officer	Jun 24 '25	Sale	33.54	2,909	97,568	56,988	Jun 26 05:25 PM
Jones Cecilia	Chief Financial Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	31,829	Jun 26 05:24 PM
Jones Cecilia	Chief Financial Officer	Jun 24 '25	Sale	33.54	1,780	59,701	30,049	Jun 26 05:24 PM
Milanova Tsveta	Chief Commercial Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	28,892	Jun 26 05:23 PM
Milanova Tsveta	Chief Commercial Officer	Jun 24 '25	Sale	33.54	2,770	92,906	26,122	Jun 26 05:23 PM
Goff Brian	Chief Executive Officer	Jun 24 '25	Option Exercise	0.00	38,277	0	118,151	Jun 26 05:22 PM
Goff Brian	Chief Executive Officer	Jun 24 '25	Sale	33.54	18,700	627,198	105,401	Jun 26 05:22 PM
Goff Brian	Officer	Jun 24 '25	Proposed Sale	34.41	18,507	636,826		Jun 24 04:10 PM
Milanova Tsveta	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:08 PM
Jones Cecilia	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:07 PM
Gheuens Sarah	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:05 PM
Burns James William	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:01 PM
Ballal Rahul D.	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	10,112	Jun 23 04:27 PM
CAPELLO JEFFREY D	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	6,073	Jun 23 04:25 PM
Foster-Cheek Kaye I	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	7,468	Jun 23 04:24 PM
FOUSE JACQUALYN A	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	151,340	Jun 23 04:23 PM
Ho Maykin	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	17,032	Jun 23 04:21 PM
Owen Adams Catherine	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	6,073	Jun 23 04:20 PM
Scadden David	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	17,603	Jun 23 04:18 PM
Smith Cynthia	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	10,112	Jun 23 04:17 PM
CAPELLO JEFFREY D	Director	Jun 13 '25	Option Exercise	0.00	1,977	0	3,953	Jun 17 04:16 PM
Owen Adams Catherine	Director	Jun 13 '25	Option Exercise	0.00	1,977	0	3,953	Jun 17 04:15 PM
FOUSE JACQUALYN A	Director	Apr 08 '25	Option Exercise	0.00	15,933	0	156,717	Apr 10 04:02 PM
FOUSE JACQUALYN A	Director	Apr 10 '25	Sale	25.90	7,497	194,172	149,220	Apr 10 04:02 PM
FOUSE JACQUALYN A	Director	Apr 08 '25	Proposed Sale	25.90	7,497	194,172		Apr 08 05:58 PM
Burns James William	Chief Legal Officer	Mar 01 '25	Option Exercise	0.00	13,500	0	27,130	Mar 04 04:17 PM
Burns James William	Chief Legal Officer	Mar 03 '25	Sale	35.54	4,005	142,338	18,650	Mar 04 04:17 PM
Jones Cecilia	Chief Financial Officer	Mar 01 '25	Option Exercise	0.00	7,667	0	27,510	Mar 04 04:15 PM
Jones Cecilia	Chief Financial Officer	Mar 03 '25	Sale	35.54	2,275	80,854	21,843	Mar 04 04:15 PM
Milanova Tsveta	Chief Commercial Officer	Mar 01 '25	Option Exercise	0.00	5,667	0	24,573	Mar 04 04:12 PM
Milanova Tsveta	Chief Commercial Officer	Mar 03 '25	Sale	35.54	1,681	59,743	22,892	Mar 04 04:12 PM
Goff Brian	Chief Executive Officer	Mar 01 '25	Option Exercise	0.00	26,500	0	101,139	Mar 04 04:10 PM
Goff Brian	Chief Executive Officer	Mar 03 '25	Sale	35.54	12,947	460,136	83,139	Mar 04 04:10 PM
Gheuens Sarah	Chief Medical Officer	Mar 01 '25	Option Exercise	0.00	13,500	0	55,578	Mar 04 04:08 PM
Gheuens Sarah	Chief Medical Officer	Mar 03 '25	Sale	35.54	4,005	142,338	47,098	Mar 04 04:08 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 01 '25	Option Exercise	0.00	5,577	0	10,141	Mar 04 04:06 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 03 '25	Sale	35.54	1,655	58,819	6,038	Mar 04 04:06 PM
Milanova Tsveta	Officer	Mar 03 '25	Proposed Sale	35.54	1,681	59,743		Mar 03 04:50 PM
Jones Cecilia	Officer	Mar 03 '25	Proposed Sale	35.54	2,275	80,854		Mar 03 04:49 PM
Goff Brian	Officer	Mar 03 '25	Proposed Sale	35.54	12,947	460,136		Mar 03 04:46 PM
Gheuens Sarah	Officer	Mar 03 '25	Proposed Sale	35.54	4,005	142,338		Mar 03 04:44 PM
Burns James William	Officer	Mar 03 '25	Proposed Sale	35.54	4,005	142,338		Mar 03 04:42 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 01 '25	Option Exercise	0.00	6,896	0	7,709	Feb 05 04:02 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 05 '25	Sale	34.39	2,272	78,134	5,437	Feb 05 04:02 PM
Milanova Tsveta	Chief Commercial Officer	Jan 03 '25	Option Exercise	0.00	8,476	0	21,710	Jan 07 05:05 PM
Milanova Tsveta	Chief Commercial Officer	Jan 06 '25	Sale	32.18	2,804	90,233	18,906	Jan 07 05:05 PM
Milanova Tsveta	Officer	Jan 03 '25	Proposed Sale	31.84	2,804	89,279		Jan 03 04:25 PM
Scadden David	Director	Dec 11 '24	Option Exercise	18.09	200	3,618	15,683	Dec 13 04:04 PM
Scadden David	Director	Dec 11 '24	Sale	46.28	200	9,256	15,483	Dec 13 04:04 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Nov 08 '24	Sale	56.09	772	43,301	813	Nov 13 04:14 PM
Ballal Rahul D.	Director	Nov 07 '24	Option Exercise	25.99	10,000	259,900	17,992	Nov 12 04:09 PM
Ballal Rahul D.	Director	Nov 08 '24	Option Exercise	25.99	10,000	259,900	17,992	Nov 12 04:09 PM
Ballal Rahul D.	Director	Nov 08 '24	Sale	58.19	10,000	581,911	7,992	Nov 12 04:09 PM
Ballal Rahul D.	Director	Nov 07 '24	Sale	53.52	10,000	535,236	7,992	Nov 12 04:09 PM
Burns James William	Chief Legal Officer	Nov 07 '24	Sale	52.21	21,752	1,135,775	15,700	Nov 12 04:08 PM
RAHUL BALLAL	Director	Nov 08 '24	Proposed Sale	58.19	10,000	581,894		Nov 08 04:17 PM
RAHUL BALLAL	Director	Nov 07 '24	Proposed Sale	53.52	10,000	535,241		Nov 07 04:51 PM
JAMES BURNS	Officer	Nov 07 '24	Proposed Sale	52.21	21,752	1,135,711		Nov 07 04:06 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '24	Option Exercise	0.00	7,473	0	22,700	Sep 30 04:15 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '24	Sale	49.03	2,542	124,634	20,158	Sep 30 04:15 PM
Ballal Rahul D.	Director	Aug 11 '24	Option Exercise	0.00	2,302	0	7,992	Aug 13 04:15 PM
Smith Cynthia	Director	Aug 11 '24	Option Exercise	0.00	2,302	0	7,992	Aug 13 04:12 PM
Goff Brian	Chief Executive Officer	Aug 08 '24	Option Exercise	0.00	22,691	0	89,883	Aug 12 05:15 PM
Goff Brian	Chief Executive Officer	Aug 08 '24	Sale	42.75	11,091	474,140	78,792	Aug 12 05:15 PM
Goff Brian	Officer	Aug 08 '24	Proposed Sale	42.75	11,091	474,184		Aug 08 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGIO

Agios Pharmaceuticals Inc

Upgrade your FINVIZ experience